Recent data reveal that Almirall’s EBGLYSS® (Lebrikizumab) maintained long-term disease control for up to three years in over 80% of adults and adolescents with moderate-to-severe atopic dermatitis.
Final Overall Survival Results of Datopotamab Deruxtecan in Metastatic HR-Positive, HER2 Low/Negative Breast Cancer from TROPION-Breast01 Phase 3 Trial Announced.
Sep 25th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
UCB reveals that BIMZELX[®] (bimekizumab-bkzx) has been approved by the U.S. FDA for treating psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.
Henlius and Intas get Positive CHMP Opinion for HETRONIFLY® (marketed as HANSIZHUANG in China) in Europe for first-line treatment in adults with extensive-stage small cell lung cancer.